Start Your Search
P2.17 - Treatment of Locoregional Disease - NSCLC (Not CME Accredited Session) (ID 966)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Presentations: 1
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
P2.17-30 - Serum Lipoprotein(A) Correlates with the Effect of Endostar Combined with Concurrent Chemoradiotherapy in Patients with Locally Advanced LSCC (ID 11872)
16:45 - 18:00 | Author(s): Miao Wang
The role of vascular targeting combined with concurrent chemoradiotherapy has produced many inconsistent results in locally advanced non-small cell lung cancer, especially in Lung squamous cell carcinoma [LSCC]. Lipoprotein(a) [Lp(a)] may be critical in development of tumor angiogenesis and its levels are individualized and determined genetically. The study aimed to determine whether Lp(a) is correlated with therapeutic effects of recombinant human endostatin [Endostar] combined with concurrent chemoradiotherapy for locally advanced LSCC.a9ded1e5ce5d75814730bb4caaf49419 Method
Patients with locally advanced LSCC concurrent chemoradiation therapy in our hospital from December 2007 to December 2017 were retrospectively analyzed. Patients were divided into two groups: 1) Chemoradiotherapy group [CRT group] which received weekly vinorelbine (12.5mg/m2) / carboplatin (AUC=2) concurrently with radiotherapy 60 Gy in 30 daily treatments, and 2) Endostar combination with chemoradiotherapy group (ECRT group) which received Endostar intravenous drip 1-14 days (every three weeks) concurrently with CRT. Fasting venous blood samples were collected before the treatment for The measurement of serum Lp(a) level in all patients, the effect of Endostar was assessed by stratified analysis.4c3880bb027f159e801041b1021e88e8 Result
94 patients were recruited in this study. There were 59 cases in CRT group and 35 cases in ECRT group. Overall, the median progression-free survival was 9.6 vs. 14.2 months (P=0.067) with overall survival 15.0 vs 20.6 months (P=0.114), in CRT and ECR groups respectively. The median of Lp(a) was 218mg/l. In patients with serum Lp(a) less than 218mg/l, the median PFS was 10.0 vs. 9.4 months (P=0.406) and OS was 15.4 vs. 16.3 months [P=0.958], in CRT and ECR groups, respectively. However, in patients with serum Lp(a) higher than 218ng/ml, the median PFS was 9.0 vs. 15.2 months [P=0.011] and OS was 14.0 vs. 21.1 months [P=0.055], in CRT and ECR groups, respectively. Patients with Grade 3 and above AE were observed in 32.2% vs. 34.3% (P=0.658) in CRT vs. ECR groups respectively.
The serum concentration of Lp(a) may serve as a biomarker to identify the patients who would benefit from Endostar treatment with concurrent chemoradiotherapy in stage III LSCC. Perspective study is needed to validate this finding.6f8b794f3246b0c1e1780bb4d4d5dc53
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.